Screener
United Therapeutics UTHR Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 86.1%-2.8pp | 86.6%-2.4pp | 87.9%-1.3pp | 88.6%-0.3pp | 89%+0.1pp | |
| Operating margin | 44.4%-2.6pp | 45.3%-1.6pp | 46.9%-1.0pp | 47.7%+1.3pp | 47%-1.2pp | |
| Net margin | 41.6%+1.2pp | 40.6%+0.2pp | 41.9%+0.4pp | 40.7%+0.3pp | 40.4%-0.5pp | |
| Returns | ||||||
| Return on equity | 19.3%0.0pp | 20.3%+0.3pp | 19.7%+0.5pp | 20%+1.2pp | 19.3%0.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.7×-1.5× | 4.8×-0.7× | 6.6×+1.4× | 6.4×+1.8× | 7.3×+2.9× | |
| Per Share | ||||||
| Book value per share | $139.74-5.9% | $125.02-10.7% | $148.15+11.5% | $139.33+10.5% | $148.52+23.8% | |
| Valuation | ||||||
| Market capitalization | $22.85B+13.4% | $25.99B+87.7% | $20.98B+33.2% | $18.96B+19.2% | $13.08B-12.6% | |
| Price / earnings | 17.4×+1.6× | 20.2×+8.8× | 15.7×+2.5× | 14.9×+0.6× | 10.5×-3.5× | |
| Price / sales | 7.2×+0.8× | 8.2×+3.6× | 6.6×+1.1× | 6.1×+0.3× | 4.2×-1.5× | |
| Price / book | 3.6×+0.5× | 4.4×+2.4× | 3×+0.5× | 2.9×+0.3× | 1.8×-0.8× |
FAQ
- What are United Therapeutics's profit margins?
- United Therapeutics (UTHR) runs a 86.1% gross margin and a 44.4% operating margin, with a 41.6% net margin.
- Where do United Therapeutics's ratios come from?
- Every ratio is computed from United Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
